New Cancer Vaccine Triggers Powerful Immune Response In Nearly 99% Of Patients

An experimental vaccine targeting one of the deadliest forms of cancer has produced an encouraging result in a clinical trial, with nearly 99% of evaluated patients developing an immune response against mutations linked to pancreatic cancer. The findings have attracted attention because pancreatic cancer remains particularly difficult to treat, especially when it returns after surgery and chemotherapy.

Researchers say the results offer valuable evidence that the immune system can be trained to recognize cancer-associated genetic mutations. However, there is still a major hurdle ahead. The vaccine has demonstrated a strong biological response, but researchers have yet to establish whether it can significantly prevent pancreatic cancer from returning.

Experimental Vaccine Produces A Strong Immune Response

Researchers led by Mayo Clinic investigators tested an experimental vaccine called camupepimut, also known as ELI-002 2P, in a randomized Phase 2 clinical trial. The treatment was developed to help the immune system recognize and attack cancer cells carrying specific mutations in the KRAS gene, which plays an important role in pancreatic cancer development.

The trial included 144 patients with stage 1 to stage 3 KRAS-mutated pancreatic cancer. All participants had previously undergone surgery and chemotherapy, and none had visible signs of cancer on imaging scans when they entered the study. Researchers randomly assigned 96 patients to receive the vaccine, while the remaining 48 were placed in an observation group.

The most striking result came from the patients whose immune responses could be evaluated after vaccination. Of the 90 vaccinated patients assessed, 89 developed increased T-cell responses against mutated KRAS.

This represented 98.9% of the evaluated group, suggesting that the vaccine successfully activated the immune system in almost every patient whose response was measured.

More than 80% of the evaluated patients also developed KRAS-specific T-cell responses that were over nine times stronger than their levels before vaccination. The findings were published in the medical journal Nature Medicine and provided researchers with important information for planning the next stage of clinical testing.

Dr. Ben George, a Mayo Clinic medical oncologist and lead author of the study, explained the significance of the findings. “Historically, pancreatic cancer has been very difficult to treat with immunotherapy,” Dr. George said, adding that researchers were encouraged by their ability to generate strong immune responses against KRAS mutations in nearly every evaluated patient.

Why The KRAS Gene Is A Major Target

The focus on KRAS is particularly important because mutations in this gene are found in approximately 90% of pancreatic ductal adenocarcinomas. This is the most common form of pancreatic cancer and accounts for much of the disease’s treatment burden. These genetic changes can help cancer cells grow and survive, making KRAS an important target for researchers developing new treatment strategies.

Normally, the KRAS gene helps regulate signals involved in cell growth and survival. When certain mutations occur, however, these signals can become disrupted, allowing abnormal cells to multiply. This can contribute to the development and progression of cancer, making it difficult for the body to control the disease through its usual defenses.

Researchers designed camupepimut to target seven of the most common KRAS mutations associated with pancreatic cancer. This gives the vaccine a potentially wider application than treatments created specifically for one patient’s individual tumor. Patients would still need to have a tumor carrying one of the mutations targeted by the vaccine to be eligible for this approach.

How The Vaccine Teaches Immune Cells To Attack Cancer

Camup​​epimut works by directing immune-stimulating components toward the lymph nodes, which are important locations where immune responses begin. The vaccine uses peptides that bind to albumin, a protein found in the bloodstream, helping deliver these components to lymph nodes. This process is intended to activate immune cells that can recognize cancer-related mutations.

One of the main targets is the body’s T cells, a type of white blood cell involved in identifying and attacking abnormal cells. Once activated, these cells can recognize specific molecular features associated with cancer. Researchers found that the vaccine stimulated two important types of T cells during the clinical trial.

CD4 T cells help coordinate immune activity and support other immune cells involved in fighting abnormal cells. CD8 T cells can recognize specific targets and attack cells carrying those abnormal features. Activating both types could help create a more coordinated immune response against cancer cells with the targeted KRAS mutations.

Unlike preventive vaccines that protect people against infections, therapeutic cancer vaccines are designed to help the immune system recognize and attack existing cancer cells or remaining cancer-related targets after treatment. Camupepimut is being investigated as a treatment approach for patients who have already undergone surgery and chemotherapy.

Did The Vaccine Actually Stop Pancreatic Cancer From Returning?

Despite the impressive immune response, the trial did not meet its primary goal of demonstrating a statistically significant improvement in disease-free survival across the entire study population. This is an important distinction because activating the immune system does not automatically mean that a treatment can prevent cancer recurrence or extend a patient’s life.

Disease-free survival measures the amount of time patients remain alive without their cancer returning or progressing. In the trial, the median disease-free survival was 23.8 months among patients who received the vaccine, compared with 21.2 months in the observation group. Although the vaccinated group had a longer median result, the difference was not statistically significant.

Researchers therefore cannot conclude that camupepimut prevents pancreatic cancer from returning. The study was designed to investigate both the vaccine’s biological effects and its potential clinical benefits, but the primary survival result did not establish a significant advantage for vaccination across all participants.

However, researchers identified an association between stronger immune responses and longer periods without disease recurrence. Patients who developed more powerful KRAS-specific T-cell responses tended to remain disease-free longer than those who developed weaker responses. This observation came from an exploratory analysis, meaning it requires further investigation before researchers can draw firm conclusions.

An October 23, 2026 update from Memorial Sloan Kettering Cancer Center also highlighted encouraging findings from the AMPLIFY-7P trial. According to the report, 75.7% of vaccinated patients remained free of recurrence during the first six months, compared with 61.7% of patients in the observation group.

These early findings provide another reason to investigate the vaccine further, although they do not establish a statistically significant long-term survival benefit. The larger clinical trial will need to determine whether the promising immune activity translates into meaningful improvements for patients.

Researchers Found Clues About Which Patients May Benefit

Another important part of the research involved examining why some patients appeared to develop stronger immune responses than others. Researchers investigated several biological factors that could potentially help identify patients more likely to benefit from the vaccine. Two areas of particular interest involved circulating tumor DNA and previous radiation treatment.

Blood Tests May Help Identify Remaining Cancer

Circulating tumor DNA, commonly called ctDNA, consists of small fragments of genetic material released into the bloodstream by cancer cells. These fragments can sometimes be detected through blood testing, providing researchers with information about cancer activity that may not be visible on conventional imaging scans.

Detecting ctDNA after cancer treatment can indicate that some cancer cells may remain in the body. This can be particularly important for pancreatic cancer patients because the disease has a high risk of returning even after apparently successful surgery and chemotherapy.

In a planned analysis, researchers observed a signal of longer disease-free survival among patients who had no detectable ctDNA when they entered the trial. This suggests that the amount of detectable cancer-related DNA in the bloodstream could potentially help identify patients who respond differently to the vaccine.

However, the findings do not establish ctDNA status as a definitive way to determine who should receive camupepimut. Researchers will need to investigate this relationship further in larger clinical studies.

Previous Radiation Treatment May Influence Immune Activity

Researchers also identified differences associated with previous radiation therapy. Patients who had received radiation treatment had fewer lymphocytes, which are white blood cells that play important roles in the body’s immune defenses. These patients also developed weaker KRAS-specific immune responses after receiving the experimental vaccine.

Among patients who had not received radiation therapy, researchers observed a signal of longer disease-free survival with vaccination. This finding suggests that previous cancer treatments could influence how effectively the immune system responds to a therapeutic vaccine.

The researchers are interested in understanding these differences because patients with pancreatic cancer often receive several forms of treatment. Knowing how those treatments affect immune activity could help researchers design future trials and identify patient groups that may benefit most.

The Vaccine Produced An Additional Immune Effect

Researchers also observed a phenomenon known as antigen spreading in a small group of vaccinated patients. This occurs when the immune system begins recognizing additional cancer-related targets beyond those specifically included in the original vaccine.

In the camupepimut study, researchers found that the immune system began responding to other cancer-associated targets that were not directly included in the vaccine. This observation attracted interest because cancer cells can carry several abnormal molecular features, potentially giving the immune system additional targets to recognize.

The finding could offer an important direction for future research into cancer immunotherapy. If a vaccine helps initiate a response that eventually expands to other cancer-related targets, it may provide a broader immune response than initially intended. However, researchers have not yet established how much antigen spreading contributes to preventing cancer recurrence.

The duration of the immune response was another encouraging finding. Among patients who could be evaluated at least 46 weeks after vaccination began, 95.5% continued to show detectable KRAS-specific T-cell responses. This suggests that the vaccine can produce immune activity that persists well beyond the initial vaccination period.

Researchers will need longer follow-up to understand whether these lasting immune responses translate into better clinical outcomes. The available findings demonstrate that the immune system can recognize the targeted mutations, while the question of whether this recognition changes the course of the disease remains open.

Why An Off-The-Shelf Cancer Vaccine Could Be Important

Camup​​epimut has another feature that could make it attractive if future clinical trials demonstrate meaningful benefits. It is an off-the-shelf vaccine, meaning it can be manufactured in advance and stored for use in eligible patients. This differs from personalized cancer vaccines, which are created using information obtained from an individual patient’s tumor.

Personalized vaccines are designed to help the immune system recognize specific characteristics of a patient’s cancer. Although this approach offers opportunities for individualized treatment, manufacturing a separate vaccine for each patient can be time-consuming and expensive. A ready-made treatment could potentially reduce these challenges and make vaccination easier to arrange.

Dr. Eileen O’Reilly, a medical oncologist and pancreatic cancer specialist at Memorial Sloan Kettering Cancer Center, helped lead the clinical research. She discussed the potential advantages of having a vaccine that could be manufactured in advance.

“Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” Dr. O’Reilly said.

The distinction could become important if camupepimut eventually proves effective in larger clinical trials. A treatment that does not require individual manufacturing could potentially be made available to more eligible patients without the same production delays associated with personalized approaches.

Researchers are also investigating personalized mRNA cancer vaccines for pancreatic cancer. These use information from an individual’s tumor to help train the immune system to recognize cancer-related proteins. Both approaches are moving through clinical research, offering scientists different ways to investigate how immune responses can be directed against pancreatic cancer.

What Happens Before The Vaccine Can Become A Treatment?

The next major step is a larger Phase 3 clinical trial designed to determine whether camupepimut can delay or prevent pancreatic cancer from returning. Phase 3 trials generally involve larger patient populations and are designed to provide stronger evidence about a treatment’s effectiveness and safety.

Researchers will need to determine whether the vaccine improves disease-free survival and whether any potential benefits extend to overall survival. They will also investigate whether patients with particular biological characteristics respond better and whether combining the vaccine with other cancer treatments could improve outcomes.

The Phase 2 findings provide a useful starting point, but several questions remain unanswered. The trial did not demonstrate a statistically significant improvement in disease-free survival across the full patient population, and overall survival results are not yet available.

For now, camupepimut remains investigational and should not be considered an established treatment for pancreatic cancer. The findings also do not mean that patients should delay or replace recommended cancer treatment while waiting for further vaccine research.

Researchers have demonstrated that they can teach the immune system to recognize KRAS mutations in almost every evaluated patient. The next clinical trial must establish whether that immune response can keep pancreatic cancer from returning and give patients more time without the disease.